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Genomic and proteomic determinants of lower
extremity revascularization failure: Rationale and
study design
Peter R. Nelson, MD , Kerri A. O’Malley, PhD , Robert J. Feezor, MD , Lyle L. Moldawer, PhD , and
James M. Seeger, MD, Gainesville, Fla
This translational research program applies a working model of advanced functional genomics/proteomics and bioin-
formatics to human peripheral arterial occlusive disease (PAOD). It is a multidisciplinary collaborative effort of clinicians,
scientists, and statisticians with an advisory panel consisting of experts in inflammation biology, vascular biology,
molecular genetics, bioinformatics, clinical trial design, and epidemiology. The proposed human initiative is designed to
study 300 symptomatic patients with PAOD undergoing medical management with or without vascular intervention by
lower extremity angioplasty/stenting or vein graft bypass. The study aims to test the hypothesis that the systemic
inflammatory response after vascular intervention influences the local milieu responsible for vascular repair and
adaptation. The expectation is that this response is not uniform in all patients but, rather, is modulated by either
preoperative genetic predisposition or postprocedure differential regulation of the innate immune response to injury that
promotes a maladaptive phenotype leading to intervention failure. Therefore, some of these differences may be present
and detectable before intervention and amenable to class prediction and prospective treatment strategies, whereas others
may be detectable in the early postprocedural period, before the onset of clinical failure, permitting interventions to
prevent an adverse outcome. The combination of genomic/proteomic data together with functional and quality-of-life
outcome measures to define a critical model for class prediction and analysis should lead to new knowledge about failure
mechanisms of vascular intervention and new strategies to improve existing approaches to lower extremity revascular-
ization. (J Vasc Surg 2007;45:82A-91A.)Outcomes after lower extremity revascularization for
peripheral arterial occlusive disease (PAOD) continue to be
disappointing. Conventional wisdom suggests 5-year by-
pass patency rates of 60% to 80%,1-6 but more recent
information indicates a concerning 1-year primary patency
rate of only 61% for vein bypass.7 Outcomes are less well
defined for angioplasty/stenting, but primary patency rates
of 70% to 90% at 3 months that drop to an unacceptable
20% to 50% at 1 to 3 years have been described.8-10
Furthermore, these results are continually being scruti-
nized in the context of about 80% improvement in patients
with intermittent claudication treated with conservative
measures such as smoking cessation, risk factor modifica-
tion, and structured exercise,11-13 and reports of poor
functional and quality-of-life outcomes despite successful
revascularization.14,15
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82AUnfortunately, understanding is poor of the disease
process of lower extremity PAOD, the arterial response to
angioplasty, the vein graft response to arterial hemodynam-
ics, or what metrics constitute the definition of success or
failure of such interventions. As a consequence, without a
defined evidence-based approach to symptomatic lower
extremity PAOD, management decisions are frequently
made without a clear understanding of how to individualize
the treatment to optimize patient outcomes.16-18
Research during the last decade has shifted away from a
focus on local mediators at sites of vascular injury as the
stimulus for vascular smooth muscle cell pathology leading
to inward vessel remodeling and end-organ ischemia. Cur-
rent theory holds that the blood vessel response to injury
may be intimately linked to the host’s systemic inflamma-
tory response, and that negative remodeling may be driven
by these systemic factors.19-22 In patients with atheroscle-
rosis, this association has been established globally (ie,
serum C-reactive protein),23 but a detailed understanding
of the systemic pathways and mechanisms that direct local
blood vessel wall adaptation to physical perturbations re-
mains lacking. The critical role that systemic inflammation
plays in directing local responses to vascular injury at the
time of intervention is the topic of another component of
this supplement (see Ozaki, “Cytokines and the early vein
graft: Strategies to enhance durability”). However, despite
the important findings reviewed in that article, decades of
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substantial progress toward more durable peripheral inter-
ventions.
GENOMIC/PROTEOMIC APPLICATION TO
HUMAN VASCULAR DISEASE
A paradigm shift has occurred recently away from the
focused study of local factors in the vessel wall and toward
the study of the influence of systemic inflammation on
these local events that ultimately leads to revascularization
failure. This new approach has been partly fueled by a
broad-based human initiative taking advantage of advances
in the sequencing of the human genome and the develop-
ment of high throughput genomic and proteomic analyses.
This sort of approach opens further avenues of discovery
into specific single nucleotide polymorphisms (SNPs)
linked to intervention failure, gene expression profiles or
molecular signatures in the interactome that predict suc-
cessful or unsuccessful outcomes, pharmacogenomic mark-
ers that might help direct anti-inflammatory treatments,
and complex genotype-environmental interactions that ul-
timately determine outcome.24 In this way, through a
systems biology approach, we are empowered to translate
changes in basic building blocks (ie, gene sequence) to
changes in gene function (functional genomics), and fi-
nally, to changes in organ function or clinical phenotype
(physiologic genomics).25
Little exists in the literature at present describing the
application of these methods to patients with symptomatic
lower extremity PAOD.26,27 However, because of the po-
tential impact and importance of this type of investigation,
the National Heart, Lung, and Blood Institute (NHLBI)
began a Genomics Initiative in 2000 designed to provide
funding for programs looking to correlate the vast informa-
tion, technology, and resources made available from the
Human Genome Project with the physiology and patho-
physiology of human cardiovascular disease.28 As a result,
several Programs for Genomic Applications (PGAs) and
Centers of Excellence in Genomic Studies (CEGS) have
been funded to study areas ranging from animal models of
cardiovascular disease to application of high throughput
genomics to cardiovascular system development and dis-
ease.
What is available in the literature are a number of
observational studies that have linked a putative SNP with
some aspect of cardiovascular disease—most commonly
hypertension or heart failure—or the response to a partic-
ular pharmacologic intervention. Genes associated with
cardiovascular disease in these studies include myocyte
enhancer factor-2 (MEF2A),29 connexin 37 gene in men,
plasminogen activator inhibitor 1 (PAI-1) and stromelysin
genes in women,30 5-lipoxygenase activating protein,31
leukotriene A4 hydrolase,32 lymphotoxin- gene,33 3-
hydroxy-3 methyl-glutaryl-coenzyme A (HMG-CoA) re-
ductase, A disintegrin and metalloproteinase with throm-
bospondin motifs 1 (ADAMTS-1) metalloproteinase in
statin therapy,34,35 -adrenergic receptors with -blockaderesponse,36 and cytochrome P450 2C9 (CYP2C9) and
vitamin K epoxide reductase-1 in warfarin therapy.37,38
These studies and their findings are limited because
they often offer little biologic or functional link from the
specific gene to the disease process studied. Furthermore,
they are single-institution observational studies with no
subsequent confirmatory studies, validation, or interven-
tion.39,40 This under-appreciated limitation emphasizes
the importance of a systems-wide approach to define
genomic signatures and pattern recognition of genomic
classifiers, with validation coming from the application of
such classifiers to other populations (ie, to related patient
cohorts or between similar cohorts in a multicenter study
design).24
The CardioGene Study is an example of an investiga-
tion using comprehensive high throughput genome-wide
molecular approaches to study clinical restenosis in bare-
metal stents used in the treatment of coronary artery dis-
ease.41 The goal is to identify genetic determinants or
predictors of inward remodeling and in-stent restenosis to
explain the dichotomous outcome of failure after percuta-
neous coronary intervention. The study is a collaborative
initiative between the NHLBI and two clinical sites in the
United States and plans to enroll 350 patients. Blood is
sampled before the intervention and then again at 2 weeks
and 6 months after intervention. Clinical end points in-
clude symptomatic restenosis at 6 months and at 12
months.
Genomic studies are performed on circulating leuko-
cytes and mononuclear cells using the Affymetrix U133A
GeneChip platform (Affymetrix, Santa Clara, Calif). Plasma
proteomic studies are performed using multidimensional
liquid chromatography and tandem mass spectroscopy.
The investigators’ initial focus is on gene regulatory
regions and transcriptomes associated with modulation
of gene expression. They are then planning a secondary
genome-wide analysis to identify genes or clusters of
genes related to in-stent restenosis and unfavorable out-
comes. This will include investigation of candidate SNPs
linked to stent failure. They plan a complex bioinformat-
ics approach to define genomic biomarkers that would
allow risk-stratification before intervention and may lead
to development of new techniques to prevent coronary
stent restenosis and failure. Results from this trial are not
yet available but are eagerly awaited because of the
parallel nature of our study design for application of
these methodologies to failure after lower extremity
revascularization.
STUDY DESIGN
Patient selection. Eligible patients are identified
amongst all patients being evaluated for symptomatic
PAOD in our current vascular surgical practice. The sum-
mary of specific inclusion and exclusion criteria are listed in
Table.42
Study overview. A 5-year study is underway in which
300 patients undergoing evaluation for symptomatic
PAOD will be enrolled. The study cohort will consist 50
Preg
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tients undergoing additional lower extremity angioplasty
with or without stenting, and 125 patients undergoing
additional lower extremity vein bypass (Fig 1).
Data are collected prospectively with longitudinal eval-
uation to determine success or failure of the intervention
with corresponding quality-of-life measures. At the same
time points as clinical assessment, blood sampling is per-
formed for high throughput genomic and proteomic anal-
yses (Fig 2) Bioinformatics tools are then applied to recon-
cile the molecular data with clinical outcomes to arrive at
molecular profiles that correspond with success or failure of
intervention. All study patients sign informed consent un-
der an Institutional Review Board approved protocol. An
Access database (Microsoft Inc, Redmond, Wash) is cur-
rently in use to collect and store all study data, defined by
the Health Insurance Portability and Accountability Act as
Table. Inclusion and exclusion criteria
Inclusion criteria
1. Diagnosis of symptomatic PAOD—Rutherford
grade I category 3 or greater42 confirmed by
history and physical and noninvasive studies—
planned for lower extremity revascularization
2. Male or female 18 years of age
1.
2.
3.
4.
5.
6.
7.
8.
9.
No Intervention (N=50)
-Claudicants
-CLI with no intervention
(genomic/proteomics of PAOD)
LE ang
(N
300 Patien
Fig 1. Study overview. LE PAOD, lower extremity per
ABI, ankle-brachial index; SF-36, Short Form 36.
Fig 2. Study timeline. ABI, Anklea “limited data set.”Clinical outcomes. Evaluation of patients for symp-
tomatic PAOD follows current standards of practice.42-44
Generally, patients with severe claudication or critical limb
ischemia (Rutherford grade I, category 3 level disease)42
are considered for intervention. In an effort to optimize
patient outcomes45,46 and standardize patients with respect
to medications that likely influence systemic inflammatory
response profiles, all patients receive antiplatelet therapy
(81 mg acetylsalicylic acid daily) and statin (HMG-CoA
reductase inhibitor) therapy (at least atorvastatin 10 mg
daily). Statin therapy is adjusted according to the recent
National Cholesterol Education Program Adult Treatment
Panel III revised national guidelines and recommenda-
tions.47 Those with a normal cholesterol profile will be
maintained on 10 mg atorvastatin daily except in patients
with documented intolerance to statins.
Patients requiring intervention will then go on to lower
Exclusion criteria
years of age
ting medical condition(s) with resulting life expectancy less than
year
umented intolerance or allergy to aspirin and clopidogrel
tory of immunosuppression on the basis of a pre-existing medical
dition or immunosuppressant therapy or chronic corticosteroid
apy to treat a preexisting condition
umented active or quiescent autoimmune disorder
ite blood cell count3.5  109/L
elets  50  109/L
patient who has received experimental drug(s) (including exper-
ntal biologic agents) within the previous 3 months
nancy
ty/stent
)
LE vein bypass
(N=125)
h LE PAOD
al arterial occlusive disease; CLI, critical limb ischemia;
hial index; SF-36, Short Form 36.18
Exis
one
Doc
His
con
ther
Doc
Wh
Plat
Any
imeioplas
=125
ts wit
ipherextremity arteriography with treatment decisions guided by
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recommendations.42,44 For patients undergoing percuta-
neous intervention, primary angioplasty is the preferred
initial approach for superficial femoral and popliteal artery
stenoses, with subintimal recanalization and angioplasty for
chronic total occlusions.48-50 Primary angioplasty is also
performed for infragenicular tibial artery stenoses or occlu-
sions in patients with critical limb ischemia.51-53 Selective
stenting is indicated for unacceptable results after angio-
plasty, including significant lesion recoil with residual ste-
nosis or flow-limiting dissection.54
For patients undergoing vein bypass surgery, a nonre-
versed anatomic bypass using ipsilateral great saphenous
vein is the approach of choice, with alternatives considered
as the specific case warrants. No synthetic bypass patients
will be included.
All patients are placed on an antiplatelet regimen con-
sisting of acetylsalicylic acid (81 mg daily), with the addi-
tion of clopidogrel (75 mg daily) for 30 days in patients
undergoing angioplasty/stent procedures. Warfarin is ini-
tiated for bypass grafts with compromised outflow55 and
continued in all patients with pre-existing indications.
Clinical and laboratory data will be collected prospec-
tively from all patients to determine preoperative risk fac-
tors and postoperative response to revascularization. The
timing of assessment and data collection is summarized in
Fig 2 and is scheduled in accordance with current standard
practice for surveillance after lower extremity intervention.
As indicated, evaluation includes review of symptoms, pulse
exam with ankle-brachial index (ABI), and duplex ultra-
sound examination of the revascularized region. Repeat
angiography is performed selectively in patients undergo-
ing evaluation for reintervention or salvage with failure of
revascularization defined according to the Society for Vas-
cular Surgery Recommended Standards for Reports Dealing
with Lower Extremity Ischemia (revised version).43
Functional and quality-of-life assessments. Func-
tional and quality-of-life measures are obtained at the same
time intervals indicated in Fig 2. Subjective patient data on
function is obtained through history and reconciled with
objective data obtained using walking exercise tolerance.
Baseline values are assessed before the intervention using a
timed, monitored walk to failure. Distance at the 6-minute
mark is documented for subsequent comparison. After the
intervention, the 6-minute walk is then used for follow-up
functional assessment.56,57 Distance achieved and before
and after exercise ABIs are recorded and compared with
preintervention measurements. Quality-of-life instruments
used in this study include both generic health and disease-
specific quality-of-life questionnaires. The Medical Out-
comes Short Form-36 (SF-36)58 serves as the generic
health questionnaire and the Vascular Quality of Life
(VascuQol)59 questionnaire measures specific elements of
PAOD to capture more subtle disease-specific effects of
intervention. Results are compared with preintervention to
determine the impact of intervention on quality-of-life.
These data are then compiled with clinical outcome data
into the time course correlative analysis in concert withgenomic and proteomic information as part of the class
prediction model discussed subsequently.
Genomic/proteomic analysis. Molecular analyses are
performed on peripheral venous blood and include evalua-
tion of the transcriptome from a total leukocyte population
and an enriched monocyte population, as well as the pro-
teome from the plasma fraction. Initial blood samples are
obtained in the preoperative holding area immediately be-
fore the procedure. Subsequent samples are taken 2 hours
and 1 day postoperatively and then at 1 week and 1, 6, and
12-months of follow-up (Fig 3).
At each time point, 15 mL of blood is sampled to
establish genomic and proteomic inflammatory response
profiles. All samples are deidentified and assigned a study-
specific identification number to assure confidentiality and
allow sample tracking. A 7 mL collection of whole blood
anticoagulated in ethylenediaminetetraacetic acid is ob-
tained for flow cytometric analysis of the peripheral blood
leukocyte phenotype, genomic analyses on the total leuko-
cyte preparation, and proteomic analyses of the plasma
fraction. Simultaneously, 8 mL of whole blood is collected
in a Becton-Dickinson CPT tube (Franklin Lakes, NJ)
containing sodium citrate to be processed further for the
isolation of an enriched blood monocyte fraction. Plasma
and leukocyte RNA are also stored for additional future
analysis if needed.
The actual protocols are detailed in two recent publi-
cations including a discussion of the advantages and limi-
tations of these analytical approaches.25,60 They are also
available through the Large Scale Collaborative Research
Program (www.gluegrant.org).
For the isolation of whole blood leukocytes, each sam-
ple will be centrifuged and the plasma fraction recovered.
Erythrocytes in the buffy coat fraction are lysed, and the
leukocytes are captured by centrifugation. Total leukocyte
RNA is then isolated using a commercial kit (RNeasy,
Qiagen, Inc, Venlo, The Netherlands) with yields of 2 to 6
g/mL of blood. This will be ample because quantities
required for microarray analyses have now been reduced to
50 ng of total cellular RNA. Monocytes are isolated by
negative selection with a commercial preparation (Ro-
setteSep, StemCell Technolgies, Vancouver, British Co-
lumbia, Canada) added directly to the CPT tubes. All
leukocyte populations other than monocytes are removed
Fig 3. Timing of phlebotomy for genomic and proteomic analy-
sis. See Fig 2 for correlation with clinical outcome assessment.
WBC, White blood cells; MO RNA, monocyte ribonucleic acid.by rosetting and centrifugation across the density gradient.
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approximately 90%.25,61 The advantage of this approach is
that the desired population is isolated without the same
degree of cell activation associated with positive selection
techniques. RNA yields from monocyte-enriched fractions
are between 500 and 1000 ng of RNA.
The technology for hybridization and microarray anal-
ysis is constantly changing. Whereas, several months ago
microgram quantities of total cellular RNA were required
for starting material, the amount now required is at the
mere nanogram level. With the use of commercially avail-
able kits that generate a labeled complementary DNA
(cDNA) product for hybridization (ie, NuGEN Ovation
labeling scheme, San Carlos, Calif), the quantity of starting
material has been reduced several logs to as little as 5 ng
total cellular RNA. This permits much smaller sampling
volumes and archival of larger quantities of RNA for vali-
dation analysis.
Similar dramatic progress has occurred in the microar-
rays themselves. Increased density and better manufactur-
ing have yielded commercial arrays that demonstrate signif-
icantly improved reliability and reduced variance. The most
dramatic development has been that of the exon arrays that
have increased the density of current chip iterations to
nearly 10million tiles and the ability to look simultaneously
at alternative splicing of messenger RNA (mRNA) prod-
ucts. In these current studies, an exon array (GeneChip
Exon ST 1.0 Array System) with 1 million exon clusters
will be used. Representative examples of heat map data
output from microarray analyses are displayed in Fig 4.62
Plasma samples will be analyzed using the Luminex
100 xMAP (Multi-Analyte Profiling) System (Austin,
Fig 4. A, Representative heat map display of microarray
MODS, multiorgan dysfunction syndrome. (Used by pe
proteomic determinants of outcome in patients underg
2004;172:7103-9.)62Tex). This bead-based assay system is essentially a flowcytometric analysis using novel fluorescent beads that are
covalently linked (in the case of cytokine measurements)
to antibodies specific for individual analytes. By coupling
the specificity of antibody-based capture of specific cyto-
kines using chromophore-labeled antibodies with flow
cytometric analyses of individual reactions identified by
unique fluorescent beads, the analytical system can mul-
tiplex the analysis of theoretically an unlimited number
of cytokines simultaneously from a single sample. Using
a two-laser system, the Luminex technology simulta-
neously identifies the quantity of an analyte bound to a
specific antibody, as well as its identity, critical for a
multiplex approach. Our current working Luminex plat-
form determines simultaneously the concentrations of
the following analytes: eotaxin, granulocyte-colony
stimulating factor, granulocyte monocyte-colony stimu-
lating factor, interferon-, interleukin (IL)-10, IL-
12p70, IL-13, IL-15, IL-17, IL-18, IL-1, IL-1, IL-2,
IL-4, IL-5, IL-6, IL-7, IL-8, interferon- inducible
protein-10, macrophage inflammatory protein-1, and
tumor necrosis factor-. A representative output of the
proteomic data is displayed in Fig 5.
Flow cytometric analysis of monocyte phenotype is
initiated by treating 1.5 mL of blood with an equal volume
of FACS Lysing Solution (Becton Dickinson, San Jose,
Calif). Monocyte analysis uses a combination of forward
and side scatter characteristics as well as the CD14/CD33
markers to isolate CD16bright/dim monocytes, which are
then analyzed for their expression of activation markers
(CD11b, CD18, and CD69), and human major histocom-
patibility complex II (human leukocyte antibody-D re-
lated). Events are evaluated for both their proportion of
using time series (B) and supervised analytic approaches.
ion, Feezor RJ, Baker HV, Xiao W, et al. Genomic and
thoracoabdominal aortic aneurysm repair. J Immunoldata
rmiss
oingpositive cells as well as for their mean fluorescence intensity
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for a cell surface marker and the expression quantity of that
marker on the cell surface membrane, respectively. Samples
will be acquired and analyzed on a six-parameter FACS-
Calibur machine with Cellquest Software (Becton Dickin-
son).
Bioinformatics. A laboratory information manage-
ment system has been designed to track all aspects of this
study from patient-specific clinical information to specimen
collection, RNA isolation, and labeled target complimen-
tary RNA preparation through hybridization, staining, and
scanning to publication.
Ongoing challenges are presented by the large data sets
that result from microarray experiments and proteomics
determinations along with the associated noise generated
through their analyses. Initially, low-level analyses are per-
formed to normalize and filter the data sets. A number of
academic software packages, including dChip (Affymetrix)
and robust multiple-array average (RMA), are available to
perform these critical analyses. Once these are complete,
the two major approaches for the analysis of microarray-
based gene expression studies are the unsupervised and
supervised analysis methods (Fig 4).
Unsupervised approaches, such as multidimensional
scaling, cluster analysis, and self-organizing maps, are used
in class discovery exercises to discover relationships among
genes that were not previously recognized without any a
priori assumptions. Supervised approaches are used to iden-
Fig 5. Representative proteomic heat map. MODS, M
monocyte chemotactic protein-1; IP-10, interferon-
sICAM, soluble intercellular adhesion molecule-1; TRA
treatment; IFNg, interferon-; TGFb, transforming gr
stimulating factor; GCSF, granulocyte colony-stimulatin
chemotactic protein-3; TNF, tumor necrosis factor-.
Genomic and proteomic determinants of outcome in pa
J Immunol 2004;172:7103-9.)62tify gene expression differences in predefined classes (ie,control vs experimental) or subsequent groupings of the
data (ie, patients who develop failure of their revasculariza-
tion versus those who do not). Unsupervised and super-
vised analytical approaches are not mutually exclusive and,
when used in conjunction, represent a very powerful
method for identifying relationships among genes.
Unsupervised analysis of gene expression patterns.
Unsupervised analytical methods are useful tools for class
discovery and identification purposes. One goal of unsuper-
vised analyses is to identify similarities between specimens
that were previously unrecognized. Principal component
analysis, a form of multidimensional scaling, is often useful
in the analysis of gene expression data sets to identify
similarities between specimens and to identify outliers.63
The dimensionality of the data set in principal component
analysis is reduced through identification of the principal
components. These principal components can be used to
identify similarities in expression patterns among arrays
without imposing any predefined structure.
This first step in our analysis is therefore designed to
identify similarities and differences in gene expression pat-
terns among patients with symptomatic PAOD. The next
analytical step uses academic software packages such as
Cluster and TreeView64 that are capable of performing
several widely used clustering methods, including hierar-
chic clustering and k-means clustering. Hierarchic cluster-
ing constructs a hierarchic tree of the gene expression data
in which genes and arrays whose expression are most similar
rgan dysfunction syndrome; IL, interleukin; MCP-1,
cible protein-10; MIG, monokine induced by IFN;
umor necrosis factor-related apoptosis-inducing ligand
factor-; GM-CSF, granulocyte-macrophage colony-
tor; TNF, tumor necrosis factor-; MCP-3, monocyte
d by permission, Feezor RJ, Baker HV, Xiao W, et al.
undergoing thoracoabdominal aortic aneurysm repair.ultio
indu
IL, t
owth
g fac
(Use
tientsto each other are placed on adjacent branches of a tree. In
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genes, hierarchic clustering is combined with k-means clus-
tering, a reiterative clustering method that partitions mem-
bers into a number of a priori user-specified bins. The data
set is clustered with k-means into the appropriate number
of bins, and the members of each individual bin are then
subsequently clustered using hierarchic algorithms. The
ultimate goal is to identify clusters that are biologically and
physiologically relevant.
Clustering approaches are powerful tools for identify-
ing genes in related pathways and with related func-
tion.64,65 Software tools are now available, including MAP-
PFinder66 and GenMAPP67 (Gladstone Institutes, UCSF,
San Francico, Calif), and Ingenuity Pathway Analysis (In-
genuity Systems, Redwood City, Calif),68 which identify
and display related groups of genes identified by microarray
experiments based on gene ontology classifications and
biological systems networks (Fig 6).
Supervised analysis of gene expression patterns.
Supervised learning approaches are next used to overcome
the limitations of unsupervised approaches in describing
expression profiles consistent with a specific phenotype.69
The goal of our supervised analyses is to identify gene
expression differences between patients whose lower ex-
tremity revascularization fails and those who have a success-
Fig 6. Representative display of inflammatory pathwa
www.ingenuity.com).ful outcome. We use several methods to minimize errorassociated with these approaches and optimize our discov-
ery of real differences that are potentially both statistically
and biologically significant. Significance analysis of mi-
croarrays (SAM) is used to minimize false discovery rates
through thousands of permutations of the data set. Analysis
of variance using biometric research branch array tools is
used to identify gene expression differences between the
patient outcome classes with a significance level set at a P
0.001 to identify significant probe sets with a false positive
rate of 1:1000 probe sets analyzed.
Next, leave-one-out cross-validation is used to mini-
mize the potential to over fit data by identifying patterns
resulting from chance alone without any biologic relevance
or significance. Leave-one-out cross-validation using four
different prediction models (1K-nearest neighbor [KNN],
3KNN, linear discriminant analysis, and nearest centroid) is
a reiterative process where each array is left out of the
training set in turn, and the remaining arrays are used to
identify probe sets significant at the P .001 level between
the various clinical outcomes. The significant probe sets so
identified will then be used to predict the outcome label of
the array omitted from the set. The number of correct
predictions will be used to evaluate the ability of the pre-
dictor probe sets (genes) to accurately predict a specific
clinical outcome (phenotype). Monte Carlo simulations
lysis (Ingenuity Pathway Analysis, Ingenuity Systems,y anawith 2000 permutations of the data set are then performed
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observed with “predictor probe sets” derived from the test
data set is lower than that expected by chance alone.
Finally, because longitudinal time-course data are be-
ing collected, time series analyses allows us the ability to
discover dynamic information about time-dependent gene
expression patterns, apparent co-regulation of genes or
gene clusters, and potential gene regulatory pathways that
coincide with success or failure of revascularization.70 It is
particularly important to model the early profiles of the
patients that may engender specific delayed end points. It is
typical to analyze time-course data using procedures based
on parametric time-series analysis, perhaps using Fourier
type models or other parametric forms.71,72 Recent reports
demonstrate progress in using nonparametric models,
however, particularly those based on functional data anal-
ysis.73-75 Using such a functional data analysis approach
offers us the ability to capture subtle profile changes in
patient response and, combined with functional principal
component analysis, to uncover and describe the differ-
ences in the genomic temporal profile of patients who have
a successful outcome vs those that go on to failure.
DISCUSSION
The critical questions asked in this study are derived
from the study’s original aims. The two broad sets of
variables to consider are (1) clinical, which consists of
anatomic, functional, and quality-of-life variables; and (2)
genomic/proteomic profile results. With such a compre-
hensive study design and the use of state-of-the-art high
throughput molecular and bioinformatics techniques, we
expect to arrive at answers to the questions that follow:.
First, can we prospectively develop a class prediction
model for gene expression profiles in 300 patients to iden-
tify a pattern of host gene expression in either the total
leukocyte or monocyte population that discriminates be-
tween patients whose revascularization with either angio-
plasty/stenting or vein bypass later fails and those who do
not?
Furthermore, can we detect perhaps subtle but critical
differences in the response to intervention between patients
undergoing angioplasty/stenting vs those undergoing vein
bypass surgery? Class prediction is perhaps the low-hanging
fruit, and ultimately, we intend to apply these technologies
to better understand the underlying biology that deter-
mines outcome. For example, from these genomic and
proteomic patterns, what can we learn about the underly-
ing inflammatory processes in blood monocytes and leuko-
cytes in patients with PAOD?Using a pathway analysis tool,
such as Ingenuity Pathway Analysis, or gene ontologies,
can we identify cell-signaling pathways or functional mod-
ules that are differentially expressed in patients with varying
clinical outcomes, and use that information to better define
the inflammatory state of the patient?
Of more importance then, can the temporal expression
of the inflammatory cell transcriptome provide insight into
the biologic mechanisms of inward remodeling and occlu-
sive adaptation at sites of angioplasty or in the implantedvein graft leading to intervention failure? If so, can we use
this new knowledge to alter selection of patients for inter-
vention, help delineate what intervention strategy is best
suited for an individual patient, or identify potential tools
for therapeutic intervention (ie, anti-inflammatory regi-
mens) to engineer the inflammatory response and improve
outcomes after lower extremity revascularization?
At the same time, can we discover and interpret pat-
terns of gene expression apparent before surgery that are
predictive of outcome such that they may reflect the pres-
ence of pre-existing leukocyte activation or immunologic
“priming”? Are these patterns evident in the total leukocyte
population, or as we might predict, in a selected cell pop-
ulation directly involved in the inflammatory process, such
as blood monocytes? Ultimately, can we use this preinter-
vention information to guide treatment decision-making
prospectively?
Next, are patterns of gene expression from the periph-
eral blood monocytes reflective of their phenotypic
changes, as determined by cell surface expression? Are the
patterns of gene expression observed in peripheral blood
monocytes indicative of either monocyte activation or the
presence of a systemic inflammatory response to vascular
intervention? Does the pattern of gene expression in blood
monocytes better discriminate outcome than the gene ex-
pression pattern from total leukocyte populations in terms
of identifying patients whose revascularization will later
failure and those who do not?
Finally, using comparable genomic chip and proteomic
plasma measurements, is there an association between the
changes in peripheral blood leukocyte or monocyte gene
expression and their relative protein concentrations in
plasma? Although it is well established that the primary
source of inflammatory mediators in the plasma compart-
ment are not blood leukocytes, but are cells of the reticu-
loendothelial system, particularly in the splanchnic bed,76
what can we infer about an associative relationship between
plasma cytokine concentrations and leukocyte gene expres-
sion?
With so many important questions to be answered, we
are committed to making our results available to interested
members of the scientific community as quickly as possible.
Once results from this study have been peer reviewed and
are published in the scientific literature, we will post the
complete reference of the published work and experimental
details conforming to the proposed “minimum informa-
tion about a microarray experiment” (MIAME) standard
on our research web site (www.surgery.ufl.edu/Research).
This site will also include the complete data set and *.dat
files along with supplemental material and other back-
ground information pertaining to the published work.
CONCLUSION
This translational research model allows us to (1) unify a
definition of outcome after peripheral lower extremity revas-
cularization using combined metrics of standard clinical end
points (ie, patency, objective anatomic and hemodynamic
measurements), functional end points (ie, exercise tolerance
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end points (as measured by a combination of generic and
disease-specific questionnaires); (2) definemolecular evidence
that a differential inflammatory state and/or response to vas-
cular injury contributes to inward remodeling and revascular-
ization failure secondary to restenosis or occlusion at the site
of intervention through advanced high throughput genomic
andproteomic analysis; and (3) establish class predictionmod-
els for patients prone to failure of lower extremity revascular-
ization through specific transcriptome identification and anal-
ysis. This will form the basis for what is currently unavailable:
an evidence-based approach to peripheral intervention and
revascularization for symptomatic lower extremity PAOD.
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